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Does treatment of acne 
with Retin A and tetracycline
cause adverse effects?
■ EVIDENCE-BASED ANSWER
Adverse reactions to long-term tetracycline thera-
py are rare, and most will occur within 2 months
of initiating therapy (strength of recommendation
[SOR]: B, systematic review of ecological stud-
ies). Rare but serious drug reactions include a
severe cutaneous reaction, hypersensitivity syn-
drome reaction, serum sickness–like reaction,
and isolated single-organ dysfunction (SOR: B,
systematic review). 
Duration of antibiotic treatment is strongly asso-
ciated with increased bacterial resistance (SOR: B,
systematic review and 1 outcomes study), but
antibiotics for acne do not appear to interfere with
oral contraceptive efficacy (SOR: B, case-control
study and supporting expert opinion). Laboratory
monitoring is not indicated in otherwise healthy
patients (SOR: B, consistent cohort studies).
No reports have been published regarding 
long-term topical tretinoin (Retin A) therapy.
Short-term follow-up reports note no systemic
effects (SOR: C, expert opinion), no teratogenicity
(SOR: B, single case control study), and negligible
systemic absorption (SOR: B, outcome studies).
Thus, long-term topical tretinoin is presumed to
be safe (SOR: C, expert opinion and extrapolation
of pharmacologic data). 
■ EVIDENCE SUMMARY
Tetracycline
A study of the safety of tetracycline,1 which used
reports in a drug safety database and a literature
review of reported adverse events, concluded that
rare but serious events do occur with tetracycline.
Severe cutaneous adverse reaction was the most
common reported single-organ dysfunction. Other
rare events included hypersensitivity syndrome
reactions and serum sickness–like reactions. 
Since baseline rates of tetracycline use are
unknown, it is impossible to ascertain the event
rates for these rare reactions. Most of these
serious adverse events occur less than 2 months
after initiating therapy; they typically include
general symptoms such as fever, malaise, and
arthralgias, but may also include major organ
involvement. The study suggested no clear
treatment for these complications, but recom-
mended discontinuing tetracycline and avoiding
the entire tetracycline class of drugs.1 No 
evidence supports previous concerns that tetra-
cycline causes drug-induced lupus.
A systematic review confirms that treating acne
with long-term systemic antibiotics leads to
increased antimicrobial resistance.2,3 A well-
designed cohort trial showed that Propioni-bacteri-
um acnes resistance was directly related to dura-
tion of antibiotic therapy.4 This is clinically impor-
tant because resistance levels correlate with ther-
apeutic failure.2 Rotating antibiotics on a long-term
basis actually increases bacterial resistance pat-
terns and can exacerbate the problems of increas-
ing resistance and poor treatment outcomes.2
A relatively large retrospective cohort study
of oral contraceptive users in a dermatological
practice showed no difference in contraceptive
failure rates between those prescribed common
antibiotics (including tetracycline) and controls
(1.6% vs 0.96%; 95% confidence interval [CI]
for the difference, 0.81–2.1).5
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A systematic review of 8 studies reported on
777 patients taking antibiotics for acne, and
examined the need for laboratory monitoring of
long-term tetracycline users, including renal,
liver, and blood components. The authors found
only 1 adverse drug reaction (mild hyperbiliru-
binemia). They concluded that routine lab moni-
toring for all patients on long-term antibiotics for
acne rarely detects clinically concerning adverse
drug reactions and would be cost-prohibitive.6
Minor adverse side effects of tetracycline ther-
apy are reported in about 8% of patients.7 Some of
the relatively more common and benign side
effects are summarized in Table 1. 
Topical tretinoin (Retin A)
Most published studies on topical tretinoin (Retin
A) focus on the side effect of minor skin irritation.
A multicenter, double-blind parallel study10 com-
pared the safety and efficacy of 2 formulations of
tretinoin gel formulations. Adverse dermatologic
side effects commonly reported are in Table 1.
These cutaneous irritant side effects, while noted
in up to 50% of treated patients, peaked in 7 days
and decreased significantly over time.
Topical tretinoin has been in clinical use for
more than 25 years. Topical delivery results in a
very low systemic exposure; plasma retinoid levels
measured after topical use remain at or below
endogenous levels, likely due to very limited
absorption.11 Topical tretinoin is not associated
with an increased risk for major congenital disor-
ders. A retrospective study of 215 women on
tretinoin during the first trimester compared with
430 controls found that the relative risk for a major
congenital anomaly was 0.7 (95% CI, 0.2–2.3). The
authors concluded that topical tretinoin did not
increase congenital anomaly risk.12
■ RECOMMENDATIONS FROM OTHERS
No clinical guidelines have been published about
the long-term use of tetracycline or topical
tretinoin. An ad hoc committee of the American
Academy of Dermatology concluded “tetracycline
Side effects of tetracycline and topical tretinoin
Tetracycline Side-effect rates
Vaginal candidiasis8 12%
Gastrointestinal complaints8* 4%
Gram-negative folliculitis9 4%
Topical tretinoin10 Maximal observed side-effect rates
Peeling 50%
Burning 49%
Erythema 49%
Skin tightness 42%
Dryness 40%
Itching 24%
* Gastrointestinal complaints included nausea, diarrhea, black hairy tongue, esophagitis, and flatulence.
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is a rational, effective, and relatively safe drug for
use in the treatment of acne vulgaris when given
in a dosage of 1 gm or less per day for long term
therapy.”7 Other experts, more concerned with
growing antibiotic resistance, recommend steps
to help prevent increasing resistance (Table 2).
Barbara F. Kelly, MD, Martha Burroughs, MS,
AHIP, University of Colorado Health Sciences Center, Denver
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■ CLINICAL COMMENTARY
Use a judicious approach to topical
agents and systemic antibiotics
We should use a judicious approach with appro-
priate use of topical agents to treat acne. In
those cases where acne is not responding, sys-
temic antibiotics can be quite effective and very
well tolerated. Regarding antimicrobial resist-
ance of P acnes, we should avoid changing
antibiotics unnecessarily, and taper to the low-
est effective dose once the acne is well con-
trolled. I think the dictum to avoid treating with
systemic antibiotics for longer than 6 months is
not widely followed. Often, much longer cours-
es of treatment are necessary. For an individual
patient, the risk of developing resistant P acnes
is often preferable to the alternatives of inade-
quate acne control or systemic isotretinoin.
Periodic attempts should be made to discontin-
ue antibiotics when acne is well controlled,
with resumption of the same antibiotic if one
continues to be needed.
Marsha Mertens, MD, Mercy Family Medicine
Residency, St. Louis, Mo
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Treatment recommendations to reduce antimicrobial resistance
Do not prescribe systemic antibiotics if a topical medication will suffice
Avoid concomitant topical and systemic use of different antibiotics
Antibiotic therapy should continue for no longer than necessary, with a maximum period 
of 6 months
Do not “switch” or “rotate” antibiotics in patients who are not responding to therapy
Try systemic retinoids if acne fails to respond within 6 months of antibiotic therapy 
or quickly relapses
Adapted from Cooper et al.2
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